Disease Information & Support


The Word:


Generic name Ibrutinib
Pronunciation eye-broo-ti-nib
Brand name(s), other common name(s) ImbruvicaTM
Drug type  BTK inhibitor
How the drug is given By mouth

Ibrutinib has been FDA-approved to treat:

  • Patients with mantle cell lymphoma (MCL) who have received at least one prior therapy
  • Patients with chronic lymphocytic leukemia (CLL) who have received at least one previous therapy
  • Patients with CLL who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL
  • Patients with Waldenström macroglobulinemia.

Side effects needing medical attention: Low blood platelet count; diarrhea; low white blood cell count; low red blood cell count; fatigue; muscle and bone pain; swelling of legs and feet; upper respiratory tract infection; nausea; bruising; shortness of breath; constipation; rash; stomach (abdomen) pain; vomiting; decreased appetite; fever; joint pain; mouth sores; sinus infection; and dizziness.

Serious side effects: Bleeding problems; infections; decrease in blood cell counts; kidney problems; second primary cancers.


For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.

last updated on Thursday, January 29, 2015